The 2025 European Society for Medical Oncology (ESMO) Congress will take place in Berlin, Germany, from October 17 to 21, 2025. Abstracts for CStone’s two core clinical assets, CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) and CS5001 (ROR1 Antibody-Drug Conjugate [ADC]), are now available on the official ESMO website.
The CS2009 abstract only contains data from 9 patients as of May 8, 2025 (abstract submission deadline) at the trial’s initial stage, meeting ESMO’s abstract submission requirements.
CStone will disclose updated preliminary data from the ongoing Phase I dose-escalation clinical study for CS2009 at the upcoming ESMO poster presentation, in approximately 70 advanced solid tumor patients. This will be the world’s first clinical data presentation for a PD-1/VEGF/CTLA-4 trispecific antibody.
CS2009 Poster Presentation Schedule:
CS2009 Data Review Conference Call:
Following the poster presentation, CStone will host an investor meeting to discuss presented data and future clinical development plan. The Company cordially invites all investors to attend this conference call.
Chinese-language session:
English-language session:
The Phase Ib study design abstract for another core product of the Company - the ROR1-targeting ADC, CS5001 - has been published on the ESMO website and will be presented as an electronic poster (ePoster) during the congress.
CS5001 ePoster Presentation Schedule:
About CStone
CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.
For more information about CStone, please visit: www.cstonepharma.com.
IR contact: ir@cstonepharma.com
PR contact:pr@cstonepharma.com
Forward-looking statements
The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.
Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.
Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies or select “Reject all” for using only strictly necessary cookies.
